• 54,735+ CME Conference Registrations Sold
  • 164,204+ Medical Conferences
  • 297 Specialties
  • 11,705 Organizers
  • 159,471 Speakers
  • 159 Countries
  • 4,843 Cities
Duration: CME/CE Points: Faculty:
-
CME : 3

No Bone Unturned : Unraveling the Biology and Treatment for Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Acute Myeloid Leukemia and Treatment-Related Myeloid Neoplasms is organized by Cleveland Clinic Center for Continuing Education and would be held during Jan 08, 2016 - Jan 08, 2018.

The target audience for this medical event for audience including medical oncologists/ hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program. This CME Conference has been approved with a maximum of 3.0 AMA PRA Category 1 Credits.

The No Bone Unturned: Unraveling the Biology and Treatment for Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Acute Myeloid Leukemia and Treatment-Related Myeloid Neoplasms webcast features a review of disease research and clinical practice regarding the contributions of cytogenetics and molecular genetics to the biology of these disorders. Also identified is the role of novel pharmacologic therapies and innovations with transplantation to improve the care of these patient populations.

Conference Objectives are :
• Describe how research on cytogenetic abnormalities in MDS and MPN has affected scoring systems for assessing risk factors associated with MDS and MPN.
• Discuss the clinical implications of cytogenetic and molecular abnormalities on diagnosis and treatment choices in MDS and MPN.
• Critically evaluate the population impact from radiation accidents and apply them to the pathogenesis of MDS/MPN and AML
• Define the risks of developing MDS and MPN that are associated with cancer treatments, especially radiation and chemotherapies.
• Compare the safety and efficacy data from trials using combination therapies and/or stand-alone therapy and interpret their clinical implications.
• Discuss risks and benefits of alternative transplant options (cord blood transplant, reduced intensity transplant, and haplo-transplants) for patients diagnosed with MDS, MPN, or AML.

Target Audience

Oncology, Hematology Blood and Marrow Transplant

Fees

Activity Fee : Fee Details will be updated soon
Interested

Specialties

Oncology, Hematology Blood and Marrow Transplant

Convert
Onsite to Virtual Conference

Market your online event to Million plus Healthcare professionals.

Recommended